Effects of sevasemten (EDG-5506) on safety, biomarkers, and functional measures in adults with Becker muscular dystrophy: results of a phase 1b, open-label study.
An oral muscle-protective drug stabilized muscle function over two years in people with Becker muscular dystrophy, encouraging further study.
Sevasemten (EDG-5506), an oral fast myosin ATPase inhibitor, demonstrated 24-month tolerability and durable reduction in muscle injury biomarkers in 12 adults with Becker MD, with functional stabilization vs expected decline. These phase 1b data support further development of sevasemten for BMD and potentially Duchenne MD.
What the study was
- Study design
- Phase 1b open-label dose escalation clinical trial
- Population
- Ambulatory adults with Becker muscular dystrophy (BMD), aged 18-55 years
- Sample size
- 12
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- EBioMedicine
Why it surfaced
First phase 1b data with 24-month follow-up for sevasemten in Becker MD — novel oral mechanism (fast myosin ATPase inhibitor) showing durable biomarker improvement and functional stabilization in a rare disease with no approved disease-modifying therapy. Sponsor-affiliated authors; functional stabilization in 12 patients warrants further monitoring.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.